Speaker illustration

Doctor Genmin Lu

Portola Pharmaceuticals Inc, South San Francisco (United States of America)

Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI)

Event: ESC Congress 2018

Topic: Thrombosis, Bleeding

Session: Platelets, haemostasis and coagulation


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb